Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Reactogenicity of Pn-MAPS30plus in Infants
NCT07406347Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- Jan 2027
- Primary completion
- Oct 2028
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, single-blind trial of GSK5459248 in bacterial pneumonia (2 arms), sponsored by GSK. Primary endpoints: Number of participants with solicited administration site adverse events, Number of participants with solicited systemic adverse events and 2 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
GSK5459248
03
Conditions
bacterial pneumonia
Beyond the preview
Go deeper on NCT07406347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406347.